BlackRock Posts Mixed Q3 Earnings; Bullish View On Immunovant
- October 13th, 2023
- 650 views
BlackRock, Inc. (NYSE: BLK), an investment management and financial services company, reported third-quarter 2023 adjusted earnings per share (EPS) of $10.91, surpassing the consensus EPS estimate of $8.26. However, the company's revenue for the period stood at $4.522 billion, slightly below analysts' expectations of $4.54 billion.
$BLK was trading at $630.00 in pre-market, reflecting a decrease of $6.17 (-0.97%).
In other news, UBS has upgraded Immunovant, Inc. (Nasdaq: IMVT), a biopharmaceutical company, from Neutral to Buy and raised the price target from $18 to $55.
Despite closing at $35.28 on Thursday, the adjusted price target indicates a potential upside of $19.72 or about 55.86% for $IMVT, based on the financial services firm's analysis
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
Treasury Targets Family Members and Associates of Maduro Regime
December 20th, 2025Herbal Works Inc. Supports President Trump's Order Easing Restriction on Cannabis
December 18th, 2025Herbal Works Inc. Plans on Expansion of Product Line in 2026
December 18th, 2025December 17th, 2025Crown Equity Holdings Inc. Announces Changes to Board of Directors
December 16th, 2025




Member Login